Olmesartan medoxomil INN 20mg + hydrochlorothiazide BP 12.5mg/tablet (f.c).30's pack: 300.00 MRP
Dosage & Administration:
The usual recommended starting dose of Olmesartan Medoxomil is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose may be increased to 40 mg. No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance>40 ml/min) or with moderate to marked hepatic dysfunction.
Hydrochlorothiazide is effective in doses between 12.5 mg and 50 mg once daily. Replacement Therapy OlmecarTM Plus may be substituted for its titrated components.
Replacement Therapy: OlmecarTM Plus may be substituted for its titrated components. Dose Titration by Clinical Effect The dose of OlmecarTM Plus tablet is one tablet once daily. More than one tablet daily is not recommended. OlmecarTM Plus tablet may be administered with other antihypertensive agents. A patient whose blood pressure is inadequately controlled by Olmesartan or Hydrochlorothiazide alone may be switched to once daily OlmecarTM Plus tablet. Dosing should be individualized. Depending on the blood pressure response, the dose may be titrated at intervals of 2-4 weeks. If blood pressure is not controlled by Olmesartan alone, Hydrochlorothiazide may be added starting with a dose of 12.5 mg and later titrated to 25 mg once daily. If a patient is taking Hydrochlorothiazide, Olmesartan may be added starting with a dose of 20 mg once daily and titrated to 40 mg, for inadequate blood pressure control. If large doses of hydrochlorothiazide have been used as monotherapy and volume depletion or hyponatremia is present, caution should be used when adding Olmesartan or switching to OlmecarTM Plus tablet, as marked decreases in blood pressure may occur. Consideration should be given to reducing the dose of Hydrochlorothiazide to 12.5 mg before adding Olmesartan. The antihypertensive effect of OlmecarTM Plus tablet is related to the dose of both components over the range of 10 mg/12.5 mg to 40 mg/25 mg. Patients with Renal Impairment: The usual regimens of therapy with OlmecarTM Plus tablet may be followed provided the patient's creatinine clearance>30 ml/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so this combination tablet is not recommended. Patients with Hepatic Impairment: No dosage adjustment is necessary with hepatic impairment.
OlmecarTM Plus 20/12.5 tablet: Each box contains 30 tablets in blister pack.